Literature DB >> 24098832

Case report: Down-staging locally advanced head and neck cancer in an HIV infected patient in a limited resource setting.

L Masamba1, D Nkosi, D Kumiponjera.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24098832      PMCID： PMC3784938     

Source DB:  PubMed          Journal:  Malawi Med J        ISSN： 1995-7262            Impact factor:   0.875


× No keyword cloud information.
  10 in total

1.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Authors:  Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

Review 2.  Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy.

Authors:  Marshall R Posner
Journal:  Oncologist       Date:  2005

3.  The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer.

Authors:  R Hoffman; M L Welton; B Klencke; V Weinberg; R Krieg
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-04-01       Impact factor: 7.038

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy.

Authors:  Ronney F Stadler; Sharon G Gregorcyk; David M Euhus; Ronald J Place; Philip J Huber; Clifford L Simmang
Journal:  Dis Colon Rectum       Date:  2004-08       Impact factor: 4.585

6.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

7.  Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390).

Authors:  A A Forastiere; D Shank; D Neuberg; S G Taylor; R C DeConti; G Adams
Journal:  Cancer       Date:  1998-06-01       Impact factor: 6.860

8.  Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.

Authors:  Robert Haddad; A Dimitrios Colevas; Roy Tishler; Paul Busse; Laura Goguen; Christopher Sullivan; Charles M Norris; Bernadette Lake-Willcutt; Mary Ann Case; Rosemary Costello; Marshall Posner
Journal:  Cancer       Date:  2003-01-15       Impact factor: 6.860

9.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

10.  Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study.

Authors:  Stefano Pergolizzi; Anna Santacaterina; Barbara Adamo; Tindara Franchina; Nerina Denaro; Pina Ferraro; Giusy R R Ricciardi; Nicola Settineri; Vincenzo Adamo
Journal:  Radiat Oncol       Date:  2011-11-22       Impact factor: 3.481
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.